We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > Actelion

News List

Actelion announces changes to its executive team upon completion of the transaction with Johnson & J firstwordpharma
May 16, 2017
Actelion Ltd (SIX: ATLN) today announced changes to its executive team that would only take effect upon closing of the transaction with Johnson & Johnson expected towards the end of the second quarter 2017.
Actelion's fourth-quarter sales, profit rise, buoyed by Opsumit, Uptravi firstwordpharma
February 15, 2017
Actelion announced Tuesday that fourth-quarter sales reached 626.9 million Swiss francs ($622 million), up from 511.8 million francs ($507.7 million) in the year-ago period, boosted by revenue from the pulmonary arterial hypertension (PAH) treatments Opsu
Actelion's Opsumit fails in late-stage study of PAH due to Eisenmenger syndrome firstwordpharma
January 24, 2017
Actelion reported Monday that a late-stage study of Opsumit (macitentan) in patients with pulmonary arterial hypertension (PAH) due to Eisenmenger syndrome failed to meet its primary objective.

Previous page 1 2 Next page